The estimated Net Worth of Michael A. Sherman is at least $3.16 Millón dollars as of 12 May 2023. Mr. Sherman owns over 87,000 units of Chimerix Inc stock worth over $74,820 and over the last 9 years he sold CMRX stock worth over $437,670. In addition, he makes $2,644,630 as President, Chief Executive Officer y Director at Chimerix Inc.
Michael has made over 8 trades of the Chimerix Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 87,000 units of CMRX stock worth $97,440 on 12 May 2023.
The largest trade he's ever made was exercising 115,559 units of Chimerix Inc stock on 17 December 2018 worth over $753,445. On average, Michael trades about 20,143 units every 91 days since 2016. As of 12 May 2023 he still owns at least 87,000 units of Chimerix Inc stock.
You can see the complete history of Mr. Sherman stock trades at the bottom of the page.
Michael A. Sherman is the President, Chief Executive Officer, Director of the Company. Prior to joining the Company, Mr. Sherman served as the President and Chief Executive Officer of Endocyte, Inc., a biopharmaceutical company focused on developing targeted therapies for the treatment of cancer, from June 2016 until its acquisition by Novartis AG in December 2018. Prior to that, Mr. Sherman served as Endocyte’s Chief Financial Officer from October 2006 to February 2017 and as its Chief Operating Officer from June 2014 to June 2016. From December 1994 to October 2006, Mr. Sherman served in various executive roles, but most recently as Vice President of Finance and Strategic Planning from May 2004 to October 2006, of Guidant Corporation, a cardiovascular device manufacturer acquired by Boston Scientific Corporation in April 2006. Mr. Sherman serves as a director of BioSpecifics Technologies Corp. and on the Indianapolis Children’s Museum Board of Trustees. During the past five years, he also served on the Board of Directors of Mead Johnson Nutrition Company, a pediatric nutrition company. Mr. Sherman holds a B.A. in economics from DePauw University and an M.B.A. from the Amos Tuck School, Dartmouth College. Our Board of Directors believes that Mr. Sherman’s expertise and experience in the pharmaceutical industry qualifies him to serve on our Board of Directors.
As the President, Chief Executive Officer y Director of Chimerix Inc, the total compensation of Michael Sherman at Chimerix Inc is $2,644,630. There are no executives at Chimerix Inc getting paid more.
Michael Sherman is 53, he's been the President, Chief Executive Officer y Director of Chimerix Inc since 2019. There are 7 older and 4 younger executives at Chimerix Inc. The oldest executive at Chimerix Inc is Catherine Gilliss, 71, who is the Independent Director.
Michael's mailing address filed with the SEC is C/O CHIMERIX, INC., 2505 MERIDIAN PARKWAY, SUITE 100, DURHAM, NC, 27713.
Over the last 12 years, insiders at Chimerix Inc have traded over $133,441,183 worth of Chimerix Inc stock and bought 1,129,869 units worth $4,757,752 . The most active insiders traders include Patrick Machado, Pharmaceuticals, Inc. Cantex y Ernest Mario. On average, Chimerix Inc executives and independent directors trade stock every 25 days with the average trade being worth of $72,060. The most recent stock trade was executed by Michael T. Andriole on 8 August 2024, trading 1,285 units of CMRX stock currently worth $1,067.
led by an experienced antiviral drug development team, chimerix is developing novel oral antiviral therapeutics with the potential to improve quality of life for patients in multiple settings, including transplant, oncology, acute care and global health. the company’s proprietary lipid technology has given rise to two clinical stage compounds, cmx001 and cmx157, which have demonstrated the potential for enhanced activity, bioavailability and safety compared to currently approved drugs. chimerix’s lead compound, cmx001, is a broad spectrum lipid acyclic nucleoside phosphonate that inhibits double-stranded dna (dsdna) viruses including cytomegalovirus (cmv), adenovirus, bk virus, herpes simplex virus and variola (smallpox). cmx001 has completed phase 2 clinical development for the prophylaxis of cmv and is in phase 2 development for the preemption and treatment of adenovirus infection in hematopoietic stem cell transplant (hsct) recipients. to date, more than 750 patients have been dosed
Chimerix Inc executives and other stock owners filed with the SEC include: